PF-Atlas › Clinical Trials › NCT01777737

Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole

Cotrimoxazole · Phase 3

Registry ID

NCT01777737

Phase

Phase 3

Status

Terminated

Drug / intervention

Cotrimoxazole

Sponsor

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Start

2013-11-25

Enrollment

Locations

About this trial

First study to test the validity of the treatment of idiopathic pulmonary fibrosis, which causes inflammation and fibrosis (scarring) of the lung tissue, with cotrimoxazole. Cotrimoxazole may improve the clinical course of the disease through eradication of Pneumocystis jiroveci colonization and other mechanisms as inhibiting the activation of alveolar macrophages and producing alterations in the surfactant system which favours the persistent activation of the inflammatory response and the development of pulmonary fibrosis.

View NCT01777737 on ClinicalTrials.gov →

Explore related

All Cotrimoxazole trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT01777737 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.